Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) traded up 8.8% during trading on Thursday . The company traded as high as $14.76 and last traded at $14.9390. Approximately 1,091,829 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 8,193,203 shares. The stock had previously closed at $13.73.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on SLS. Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Alliance Global Partners reiterated a "buy" rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $10.00.
Get Our Latest Research Report on SLS
SELLAS Life Sciences Group Stock Performance
The firm has a market capitalization of $3.10 billion, a P/E ratio of -72.76 and a beta of 2.48. The company has a 50-day moving average price of $12.23 and a 200-day moving average price of $7.97.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01).
Institutional Trading of SELLAS Life Sciences Group
A number of institutional investors and hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System boosted its stake in SELLAS Life Sciences Group by 31,891.4% during the 2nd quarter. California State Teachers Retirement System now owns 2,987,040 shares of the company's stock worth $44,089,000 after acquiring an additional 2,977,703 shares during the last quarter. Marshall Wace LLP increased its stake in SELLAS Life Sciences Group by 23,550.0% in the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company's stock valued at $5,947,000 after purchasing an additional 2,704,007 shares in the last quarter. Geode Capital Management LLC raised its holdings in SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company's stock worth $4,819,000 after purchasing an additional 1,379,988 shares during the period. Millennium Management LLC raised its holdings in SELLAS Life Sciences Group by 341.0% in the fourth quarter. Millennium Management LLC now owns 1,387,849 shares of the company's stock worth $5,232,000 after purchasing an additional 1,073,147 shares during the period. Finally, State Street Corp raised its holdings in SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company's stock worth $8,249,000 after purchasing an additional 827,257 shares during the period. 17.38% of the stock is owned by institutional investors.
About SELLAS Life Sciences Group
(
Get Free Report)
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.
The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
